1,006 research outputs found
Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease
No full textJanssen, A (reprint author), Jessa Hosp, Clin Res Dept Cardiol, Heartctr Hasselt, Stadsomvaart 11, B-3500 Hasselt, Belgium.
[email protected]
Supplemental material for Monitoring cognitive change in multiple sclerosis using a computerized cognitive battery
No full textSupplemental Material for Monitoring cognitive change in multiple sclerosis using a computerized cognitive battery by L De Meijer, D Merlo, O Skibina, EJ Grobbee, J Gale, J Haartsen, P Maruff, D Darby, H Butzkueven* and Van der A Walt* in Multiple Sclerosis Journal-Experimental, Translational and Clinical</p
The effects of tibolone in older postmenopausal women
No full textRobert Norman and Alastair MacLennan were investigators in the LIFT TrialSteven R. Cummings, Bruce Ettinger, Pierre D. Delmas, Peter Kenemans, Victoria Stathopoulos, Pierre Verweij, Mirjam Mol-Arts, Lenus Kloosterboer, Lori Mosca, Claus Christiansen, John Bilezikian, Eduardo Mario Kerzberg, Susan Johnson, Jose Zanchetta, Diederich E. Grobbee, Wilfried Seifert and Richard Eastell for the LIFT Trial Investigator
A short history of the European Association of Preventive Cardiology (EAPC)
No full textDe Backer G, Perk J, Wood D, et al. A short history of the European Association of Preventive Cardiology (EAPC). European Journal of Preventive Cardiology . 2022: zwac027.The history of the EAPC is closely related to the history of the European Society of Cardiology (ESC). The ESC decided at the turn of the century to overcome the splitting into 27 topic related Working Groups with great differences in size and activities and to create a new organizational concept based on Associations, each having an official ESC scientific journal and an annual ESC connected congress. The European Association for Cardiovascular Prevention and Rehabilitation was built on the fundaments of epidemiology and prevention, exercise physiology, cardiac rehabilitation and sports cardiology. The official journal of the Association was launched in 2003 and the first EuroPRevent Congress was held in Athens in 2006. During the following years, the different interests of the founding working groups came closer together, which resulted in a name change of the Association into "European Association of Preventive Cardiology" and of the journal into "European Journal of Preventive Cardiology". The name change marked the migration of Preventive Cardiology to centre stage in the ESC. This document summarizes how and from where the EAPC started and where it stands now. Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2022. For permissions, please email: [email protected]
Ace inhibition and endothelial function: The perfect study, sub study of the EUROPA trial: Main findings
No full textFindings support the notion that part of the beneficial effects of perindopril on cardiovascular mobidity and mortality in the EUROPA study may be explained by improvement in endothelial function
The new Primary Care and Risk Factor Management (PCRFM) nucleus of the European Association of Preventive Cardiology: A call for action
No full textHollander, M (reprint author), Julius Ctr Hlth Sci & Primary Care, POB 85060,Stratenum 6-131, NL-3508 AB Utrecht, Netherlands.
[email protected]
The Young Community of the European Association of Preventive Cardiology: The future in motion
No full textNo abstract availabl
ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial
No full textBackground: ACE inhibition results in secondary prevention of coronary artery disease (CAD) through different mechanisms including improvement of endothelial dysfunction. The Perindopril-Function of the Endothelium in Coronary artery disease Trial (PERFECT) evaluated whether long-term administration of perindopril improves endothelial dysfunction.
Methods: PERFECT is a 3-year double blind randomised placebo controlled trial to determine the effect of perindopril 8 mg once daily on brachial artery endothelial function in patients with stable CAD without clinical heart failure. Endothelial function in response to ischaemia was assessed using ultrasound. Primary endpoint was difference in flow-mediated vasodilatation (FMD) assessed at 36 months.
Results: In 20 centers, 333 patients randomly received perindopril or matching placebo. Ischemia-induced FMD was 2.7% (SD 2.6). In the perindopril group FMD went from 2.6% at baseline to 3.3% at 36 months and in the placebo group from 2.8 to 3.0%. Change in FMD after 36 month treatment was 0.55% (95% confidence interval −0.36, 1.47; p = 0.23) higher in perindopril than in placebo group. The rate of change in FMD per 6 months was 0.14% (SE 0.05, p = 0.02) in perindopril and 0.02% (SE 0.05, p = 0.74) in placebo group (0.12% difference in rate of change p = 0.07).
Conclusion: Perindopril resulted in a modest, albeit not statistically significant, improvement in FMD
- …
